FDA approves immunotherapy combo for advanced RCCApril 17, 2018Renal Cell CarcinomaGenitourinary Cancer
Diabetes from checkpoint inhibitors probably means lifelong insulinApril 8, 2018MelanomaRenal Cell CarcinomaGenitourinary Cancer
Tivozanib after sorafenib promising in patients with advanced RCCApril 7, 2018Renal Cell CarcinomaGenitourinary Cancer
MRI matches standard biopsy at detecting significant prostate cancersMarch 27, 2018Genitourinary Cancer
Protons linked to lower urinary AEs, higher costs than with IMRT for prostate cancerMarch 22, 2018Genitourinary Cancer
Dose-escalated radiation therapy brings mixed results in prostate cancerMarch 17, 2018Genitourinary Cancer
DNA repair gene mutations predict response to anti–PD-1/PD-L1 in urothelial cancerMarch 7, 2018Immuno-oncologyGenitourinary Cancer
Excellent prognosis for cystic RCC evaluated with radiologic threshold of greater than 50%March 7, 2018Renal Cell CarcinomaGenitourinary Cancer
FDA authorizes first direct-to-consumer BRCA1/2 testMarch 6, 2018Breast CancerGenitourinary CancerGynecologic CancerPatient & Survivor Care
Avelumab safety compares with other checkpoint inhibitorsMarch 5, 2018Immuno-oncologyGynecologic CancerGenitourinary Cancer
Prostate cancer survival similar with EBRT/brachytherapy or surgery, analysts claimMarch 2, 2018Genitourinary Cancer
Axitinib/pembrolizumab combo safe, effective against mRCCFebruary 16, 2018Renal Cell CarcinomaGenitourinary Cancer
FDA approves apalutamide for castration-resistant nonmetastatic prostate cancerFebruary 14, 2018Genitourinary Cancer
Enzalutamide shines in nonmetastatic castration-resistant prostate cancerFebruary 13, 2018Genitourinary Cancer
